Skip to contentSkip to filters

We use cookies for analytics.

The FDA's psychedelic sea-change: what accelerated clinical trials for psilocybin, methylone, and ibogaine mean for mental health and neuroscience research | Boris Heifets

Related content

About

Last month we saw a big shift in the federal government’s approach to psychedelic medicine.

Specifically, following an executive order by President Trump, the FDA announced it is fast-tracking its review of several clinical trials of psychedelic drugs for patients with mental health disorders. The executive order also directed more funds towards psychedelic research and a review of psychedelics’ status as highly restricted Schedule 1 substances.

To help us understand what all this means for the future of psychedelic medicine and the neuroscience of psychedelics, we’re joined by Boris Heifets, an anesthesiologist at Stanford Medicine who runs a lab studying how psychedelics affect the nervous system and their impact on patients with psychiatric conditions.

Topics

Details

Show

From Our Neurons to Yours

19 episodes on World Wide · Stanford Wu Tsai Neurosciences Institute